Tranexamic Acid Tablet
Product Images NDC 50268-772

Product Visual Gallery

This gallery contains 5 technical images submitted to the FDA as part of the official labeling for Tranexamic Acid (NDC 50268-772). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Avpak, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

30 (772 13)

This is a prescription drug label for Tranexamic Acid in tablet form. Each unit dose contains 30 tablets (3x10). The National Drug Code (NDC) is 50268.772-13. The rest of the text seems to be illegible or corrupted, so no additional information can be provided.*

FDA Label Image

4 (Table 4)

The table presents the results of a study on women with heavy menstrual bleeding. Three groups were tested, one using Tranexamic acid USP tablets 3900 mg/day, another using Tranexamic acid USP tablets 1950 mg/day, and the third using a placebo. The results indicate that the two groups that used Tranexamic acid USP tablets had a significant mean reduction in menstrual blood loss compared to the placebo group.*

FDA Label Image

5 (Table 5)

This is a table presenting the secondary outcomes of a study conducted on women suffering from heavy menstrual bleeding. The outcomes were measured in terms of leisure activities, physical activities, and reduction in large stains. Participants were given 3900 mg/day tranexamic acid USP tablets or placebo. The table shows the number of responders and the extent to which their activities were limited. The study found that tranexamic acid led to an improvement in the frequency of large stains compared to placebo.*

FDA Label Image

Chemical Structure (Tranexamic 01)

FDA Label Image

Figure 1 (Tranexamic 02)

This is a table showing Mean Menstrual Blood Loss (mL) for a study conducted on Tranexamic acid and Placebo. The study was conducted over 3 and 6 cycles. The dosage for Tranexamic acid was 3900 mg/day. The table also shows the baseline and treatment periods.*

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.